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Abstract
Extracellular vesicles (EVs) can deliver many types of drugs with their natural 
source material transport properties, inherent long-term blood circulation capabili-
ties and excellent biocompatibility, and have great potential in the field of drug 
carrier. Modification of the content and surface of EVs according to the purpose of 
treatment has become a research focus to improve the drug load and the targeting 
of EVs. EVs can maximize the stability of the drugs, prevent immune clearance and 
achieve accurate delivery. Therefore, EVs can be described as " stealth transport air-
crafts " for drugs. This chapter will respectively introduce the application of natural 
EVs as cell substitutes in cell therapy and engineered EVs as carriers of nucleic acids, 
proteins, small molecule drugs and therapeutic viral particles in disease treatment. 
It will also explain the drug loading and modification strategies of EVs, the source 
and characteristics of EVs. In addition, the commercialization progress of EVs drugs 
will be mentioned here, and the problems in their applications will be discussed in 
conjunction with the application of EVs in the treatment of COVID-19.
Keywords: extracellular vesicles, exosomes, drug carrier, drug loading, 
targeting modification
1. Introduction
Extracellular vesicles (EVs) are a collective term for tiny vesicles with a phospho-
lipid bilayer structure that are actively secreted by cells. Almost all known cell types 
can be secreted. The two main categories of EVs are exosomes and microvesicles 
(Table 1). Exosomes (30-150 nm in diameter) are intraluminal vesicles, formed by 
the invagination of the multivesicular endosome membrane, and are released into 
the extracellular space after the multivesicular endosomes fuse with the cell mem-
brane [1]. Microvesicles (50–1,000 nm in diameter) are a group of highly heteroge-
neous EVs characterized in that their origin and secretion are budding through the 
plasma membrane [1]. Considering the complexity of identifying its biogenesis, 
the size of the vesicle is the most widely used parameter for classifying EV types, 
Vesicle Size (nm) Density (g/mL) Origin Markers
Exosomes 30-150 1.13-1.18 Endosomes Tetraspanins, Alix, TSG101
Microvesicles 50-1000 1.16-1.19 Plasma membrane Intergrins, Selectins, CD40
Table 1. 
The main characteristics of EVs [1, 2].
Theranostics - An Old Concept in New Clothing
2
and on this basis they are described as small EVs or medium and large EVs. In this 
article, unless otherwise specified, the term "EVs" generally refers to small EVs.
In recent years, people’s understanding of the biogenesis, composition, function 
and mechanism of EVs has continued to deepen [3–5]. Their application in clini-
cal treatment has also attracted more and more attention. One of the most useful 
properties of EVs is their ability to cross barriers, such as the plasma membrane 
and blood/brain barrier. This makes them very suitable for delivering therapeutic 
molecules. With their natural source material transport properties, inherent long-
term blood circulation capabilities and excellent biocompatibility, EVs can deliver 
a variety of chemical drugs, proteins, nucleic acids, gene drugs and other drugs. 
They have great potential in the field of drug carriers. CD47 is the ligand for signal 
regulatory protein alpha (SIRPα), and CD47-SIRPα binding initiates the ‘don’t eat 
me’ signal that inhibits phagocytosis. Therefore, CD47 on EVs prevents them from 
being engulfed by immune cells [6]. EVs are more efficient than their synthetic 
analog liposomes. The application of EVs as drug delivery carriers is like putting 
a "stealth coat" on the drug molecules, which can maximize the stability of the 
drugs, reduce the immune system’s clearance of them, and make "precise delivery" 
possible. Therefore, EVs can be described as "stealth transport aircrafts" for drugs. 
EVs therapy has shown great application prospects from oncology to regenerative 
medicine.
2. Therapeutic application of natural EVs as cell substitutes
A number of studies have shown that EVs derived from mesenchymal stem cells 
(MSCs) can be used for stem cell replacement therapy [7–21]. In most cases, it is not 
clear which component of the unmodified EVs exerts curative effects. The research-
ers’ operations are only the separation and purification of EVs produced by thera-
peutic cells. The curative effects are based on the biological functions of the donor 
cells, such as the regulation of the immune environment, the repair of damaged 
cells and the promotion of angiogenesis.
At present, the most extensive research is the attempt to use stem cell-derived EVs 
for disease treatment. The main application ranges are to repair and regenerate tissues 
and organs. Such researches involve central nervous system diseases [7, 8], cardiovas-
cular diseases [9–12] and other organ damage repair and regeneration [13–21].
2.1  EVs derived from stem cells and the treatment of central nervous system 
diseases
In the treatment of central nervous system disease, there is a blood-brain barrier, 
which often results in that drugs can not reach the diseased site and work well. Stem 
cells have been gradually used in the treatment of central nervous system diseases 
in recent years. A large number of research results have been obtained [22, 23]. 
However, there are still potential risks faced by direct stem cell transplantation, 
such as tumorigenicity, infection, transplant failure, graft versus host disease, 
hemorrhagic cystitis, and long-term complications [24].
The application of stem cell EVs avoids a variety of potential risks of direct 
stem cell transplantation. EVs have low immunogenicity and are easy to preserve 
and transport, showing unique advantages as a "cell-free stem cell therapy 
technology". Spinal cord injury (SCI) is one of the deadliest diseases. The complex 
inhibitory microenvironment needs to be fully mitigated. EVs derived from MSCs 
have the function of microenvironmental regulation. Studies have established 
innovative implantation strategies using human MSC-derived EVs immobilized in 
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peptide-modified adhesive hydrogels (Exo-pGel) [7]. Exo-pGel plays an important 
role in nerve recovery and urinary tissue protection by effectively reducing 
inflammation and oxidation [7]. In addition, small extracellular vesiclesderived 
from embryonic stem cells (ESC-sEVs) can significantly reduce the time-related 
aging of hippocampal neural stem cells (H-NSCs) through intravenous injection 
into vascular dementia (VD) rats. ESC-sEVs can restore the damaged proliferation 
and neuronal differentiation ability, and reverse cognitive impairment. The 
application of ESC-sEVs may be a new cell-free treatment tool for VD and other 
diseases related to aging [8].
2.2 EVs derived from stem cells and the treatment of cardiovascular diseases
Stem cells can be induced to differentiate into cardiomyocytes. Early stud-
ies believed that the transplanted stem cells can differentiate into heart cells and 
necrotic cells in the body to repair damaged myocardium and maintain heart 
function [25]. At present, a large number of preclinical studies have found that EVs 
derived from transplanted stem cells also have the function of myocardial repair 
[26, 27]. EVs mainly promote myocardial regeneration by activating cardiac precur-
sor cells, promoting the survival and proliferation of cardiomyocytes, inhibiting 
their apoptosis, promoting cardiac angiogenesis, reducing infarct size and tissue 
fibrosis, and regulating inflammation. Extracellular vesicles secreted by cardio-
vascular precursor cells (hCVPC-EVs) derived from human pluripotent stem cells 
(hPSCs) play a role in protecting the heart in myocardial infarction by improving 
cardiomyocyte survival and angiogenesis [9]. Mouse ESC-derived EVs promote 
angiogenesis, cardiomyocyte survival and proliferation, reduce cardiac fibrosis, and 
improve cardiac function by carrying miR-294-3p [10]. IPSC-derived EVs inhibit 
cardiomyocyte apoptosis through miR-21 and miR-210 loaded, and also have a car-
dioprotective effect [11]. Exosomes produced by immature bone marrow-derived 
macrophages (BMDM-exo) contain anti-inflammatory microRNA-99a/146b/378a. 
They can reduce the necrotic lesions of atherosclerosis [12].
2.3  EVs derived from stem cells and the damage repair and regeneration of other 
organs
With the continuous discovery of the repair and regeneration effects of stem 
cell EVs in brain tissue and cardiovascular tissues and organs, the application of 
stem cell EVs in the repair and regeneration of other tissues has also made a lot of 
progresses.
MSC-derived EVs reduce radiation-induced lung injury through miRNA-214-3p 
[13]. Replacing autologous cells with EVs derived from hair follicle papillary cell 
spheres can promote hair growth [14]. Human umbilical cord mesenchymal stem 
cell-derived exosomes (UMSC-Exo) can inhibit pyrolysis and repair muscle isch-
emic injury by releasing circular RNA circHIPK3 [15]. Hertwig’s EVs derived from 
epithelial root sheath cells promote the regeneration of dentin plasma tissue [16]. 
Exosomes from neural progenitor cells retain photoreceptor cells during retinal 
degeneration (RD) by inactivating microglia. This suggests that NPC-exos and its 
contents may be the mechanism of stem cell therapy to treat RD [17].
Aging is the process of cell and tissue dysfunction. Small extracellular vesicles 
(sEVs) isolated from primary fibroblasts from young human donors can improve 
certain biomarkers of cellular senescence from elderly and Hutchinson-Gilford 
progeria donors. Studies have shown that sEVs have GST activity to improve 
aging-related tissue damage [18]. In obesity diseases, EVs derived from adipocytes, 
as new adipokines, are related to the body’s metabolic homeostasis. EVs released 
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from brown adipose tissue or adipose stem cells can help control the remodeling 
of white adipose tissue, making it brown and maintaining metabolic homeostasis. 
EVs have been considered as new regulators of diseases such as insulin resistance, 
diabetes and non-alcoholic fatty liver. The results provide new treatment strategies 
for obesity and metabolic diseases [19].
In addition, some reports suggest that some EVs derived from mesenchymal 
stem cells contain some tumor suppressor molecules. For example, it has been 
reported that miR-206 in exosomes derived from bone marrow mesenchymal stem 
cells could inhibit the progression of osteosarcoma by targeting TRA2B [20]. The 
exosomes derived from human umbilical cord mesenchymal stem cells deliver 
miRNA-375 to delay the progression of esophageal squamous cell carcinoma [21]. 
However, although EVs contain these small RNAs that have been reported to exert 
anti-cancer effects, they also contain a large number of growth factors and pro-
angiogenesis factors. When these substances are transported to tumor cells by EVs, 
can EVs derived from MSCs still exert a tumor suppressor effect? This needs more 
research to prove.
At present, cell replacement therapy based on the characteristics of donor cells 
has been studied earlier and more frequently in the field of EVs. There is also a 
clearer understanding of the components that play a major role. With the continu-
ous increase of clinical needs, people began to try to modify the surfaces and 
contents of EVs to adapt to more disease treatments.
3.  Application of engineered EVs as carriers of nucleic acid drugs in 
disease treatment
Although natural EVs have been used for cell replacement therapy based on 
their source and achieved good results, their therapeutic range is far from meeting 
the current treatment needs. One of the most important therapeutic areas is the 
treatment of malignant tumors. The secretion ability of EVs in malignant tumor 
itself is enhanced and contributes to tumor progression. Considering that MSC-
derived EVs generally contain high levels of growth factors and pro-angiogenic 
factors, most natural EVs are not suitable for tumor therapy, except that EVs derived 
from antigen-presenting cells can be used as tumor vaccines to activate anti-tumor 
immune responses [28]. Based on the biological characteristics of EVs, it has 
become the focus of researchers and biopharmaceutical companies to transform 
EVs as carriers of multiple drugs.
Most diseases have characteristic down-regulation of small RNA expression. Small 
RNA is the main content of extracellular vesicles, the most abundant and the most 
easily carried component. Therefore, EVs can be used to carry and deliver small RNA 
and other gene therapy systems. This section will discuss the progress of engineered 
EVs to deliver nucleic acid drugs and the strategies of drug loading and targeting.
3.1 Research progress of engineered EVs to deliver nucleic acid drugs
There are three main problems in the development of nucleic acid drugs: the 
instability of nucleic acid molecules in the body, potential side effects and dif-
ficulties in drug delivery systems. The most important one is the development of 
delivery systems. Because a good drug delivery system can improve drug stability 
and target cell absorption efficiency, and can reduce its side effects. At present, 
the commonly used delivery vehicles in the field of nucleic acid drugs are mainly 
adeno-associated virus (AAV) and liposomal nanoparticles (LNPs). A small 
 number of companies also use lentivirus (LV) and exosomes as delivery vehicles.
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The packaging capacity of AAV is small (≤5kb). AAV will be used more than 
once in patients for therapeutic purposes and the second use will cause the body 
to produce a strong immune response. The safety of LNPs is relatively high, and 
the carrier capacity and delivery efficiency can meet the current demand for drug 
carriers. However, the organ selectivity of LNPs is still relatively limited. The main 
delivery area is concentrated in the liver, and the delivery efficiency to other tissues 
and organs is relatively low.
EVs are now candidate carriers for nucleic acid drugs by virtue of their advan-
tages. The red blood cell extracellular vesicles (RBCEVs) have a large loading 
capacity (≤11kb), can be loaded with many types (including DNA, mRNA, anti-
sense oligonucleotides, siRNA and other nucleic acid types), and contain very little 
nucleic acid. The advantages make them high-quality natural blank nucleic acid 
carriers. RBCEVs can be delivered to many different organs and tissues. In mouse 
experiments, the delivery effects of lung, liver, kidney, bone tissue, immune cells, 
etc. are all obvious [29]. Moreover, the raw materials used to produce RBCEVs are 
mainly blood from type O blood donors. This means large quantities of raw materi-
als are readily available, and costs are controllable. Carmine Therapeutics focuses 
on the research and development of nucleic acid delivery technology using RBCEVs 
as carriers.
In addition, researchers are also committed to modifying the surfaces of EVs to 
improve their targeting. Many results show that this strategy can indeed improve 
the therapeutic effect of engineered EVs [30–33].
The researchers combined ligand-coupled superparamagnetic nanoparticles 
with specific membrane proteins of blood exosomes to achieve the separation, 
purification and tumor targeting of exosomes [30]. The chemotherapy drug 
doxorubicin (Dox) and the cholesterol-modified single-stranded miRNA-21 inhibi-
tor (chol-miR21i) were co-loaded onto the exosomes. Then the cationic endolysin 
peptide was absorbed on the negatively charged membrane surface of exosomes 
to promote the cytoplasmic release of the packaged cargo (Figure 1). The research 
results showed that these effectively released drugs and RNA simultaneously inter-
fered with nuclear DNA activity and down-regulated the expression of oncogenes, 
thereby significantly inhibiting tumor growth and reducing side effects [30].
Chimeric antigen receptors (CAR) are cell surface receptors that recognize spe-
cific proteins (antigens). Tumor cells express their specific antigens. Modification 
of EVs surfaces with CAR targeting tumor antigens enables EVs to target tumors for 
Figure 1. 
Schematic representation of engineered blood exosomes for effective gene/chemo combined antitumor therapy [30].
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drug delivery. Modified EVs with CAR can serve as a biosafety delivery platform 
for the CRISPR/Cas9 system to improve their tumor selectivity. Compared with 
unmodified EVs, CAR-EVs accumulate rapidly in tumors and effectively release the 
CRISPR/Cas9 system targeting MYC oncogenes in vitro and in vivo [31].
Rabies virus glycoprotein (RVG) is neurogenic. At present, it has become the 
most active guide molecule for brain targeted drugs. Lysosomal-associated mem-
brane glycoprotein 2b (Lamp2b) is the membrane surface protein of EVs. RVG 
fused with Lamp2b is located on the surface of the EV to achieve brain targeting. 
Engineered Lamp2b-RVG-circSCMH1-extracellular vesicles (Lamp2b-RVG-
circSCMH1-EVs) can selectively deliver circSCMH1 to the brain. The treatment can 
improve the functional recovery of mice and monkeys after stroke [32].
In addition, EVs without modification for targeting have also shown certain 
curative effects. The miR-214 inhibitor was transfected into HEK293T cells. Their 
exosomes Exo-anti-214 can reverse the resistance of gastric cancer to DDP [33]. 
HEK293T cells were transfected with HGF siRNA and their exosomes were har-
vested. In vivo and in vitro experiments have shown that exosomes loaded with 
HGF siRNA can inhibit the proliferation and migration of cancer cells and vascular 
cells [33].
3.2 Methods of loading nucleic acid drugs into engineered EVs
Methods of loading nucleic acids into EVs include: chemical reagent transfec-
tion, electroporation transfection, transfection of donor cells, protein and char-
acteristic sequence targeting methods. The application scope and advantages and 
disadvantages of different methods are shown in Table 2.
The use of proteins that can bind to specific RNA sequences (Figure 2) or the 
conservative sequences of Exosome-enriched RNAs (eRNAs) to achieve active 
packaging is a promising direction. The researchers used the specificity of protein 
binding to the RNA sequence to develop EXOtic devices for mRNA delivery [38]. 
Archaeal ribosomal protein L7Ae specifically binds to the C/Dbox RNA structure 
[40–42]. Based on this, L7Ae was conjugated to the C-terminus of CD63. C/D box 
Methods Application scope Merit and demerit References
Chemical reagent 
transfection
Broad-spectrum. Easy to operate, but EVs should 





The most commonly 
used method, but not for 
miRNA, shRNA, mRNA 
containing chemical 
modification.
Easy to operate, but EVs should 





Broad spectrum, but not for 
biotoxic molecules.
Purify EVs after transfection, 
but the effect of the transfected 
molecule on the donor cell 






mRNA and miRNA. High specificity of loading, but 
the therapeutic molecules will 
be modified. Whether this will 




Methods of loading nucleic acid drugs into engineered EVs.
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was inserted into the 3′-untranslated region (3′-UTR) of the reporter gene. 
Therefore, the mRNA encoding the reporter protein could be well incorporated 
into exosomes via the interaction between L7Ae and the C/D box in the 3′-UTR. 
Exosomes containing the RNA packaging device (CD63-L7Ae), targeting module 
(RVG-Lamp2b to target CHRNA7), cytosolic delivery helper (Cx43 S368A) and 
mRNA (nluc-C/Dbox) were efficiently produced from exosome producer cells by 
the exosome production booster. The engineered exosomes were delivered to target 
cells and the mRNA was delivered into the target cell cytosol with the help of the 
cytosolic delivery helper. Finally, protein encoded in the mRNA was expressed in 
the target cells [38] (Figure 2). In the future, researchers need to obtain more spe-
cific RNA sequence binding proteins and conserved sequences of eRNAs through 
bioinformatics analysis.
4.  Application of engineered EVs as protein transporters in disease 
treatment
The lack of protein and malfunction are important causes of many diseases. For 
example, the occurrence of malignant tumors is related to the lack of certain tumor 
suppressor factors and malfunctions. Therefore, increasing the corresponding pro-
tein level is one of the ways to treat diseases. Considering the risk of genome changes, 
researchers aim to deliver therapeutic protein molecules to the lesion through effec-
tive drug delivery vehicles. This section will introduce the use of EVs to transport 
protein molecules for the prevention and treatment of tumors, immune diseases, 
cardiovascular diseases, atherosclerosis, myocardial infarction and other diseases.
4.1  Research progress of engineered EVs as protein transporters for disease 
treatment
Compared with the previous small molecule compound drugs, protein drugs 
have the characteristics of high activity, strong specificity, low toxicity, clear biologi-
cal functions, and are beneficial to clinical application. However, protein drugs are 
unstable in the internal and external environments, and may undergo a variety of 
complex chemical degradation and physical changes, such as aggregation, precipita-
tion, racemization, hydrolysis, and deamidation. Protein drugs have short half-life, 
high clearance rate, large molecular weight, poor permeability, susceptibility to the 
Figure 2. 
EXOtic devices for mRNA delivery. A schematic illustration of the EXOtic devices [38].
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destruction of enzymes, bacteria and body fluids in the receptor, and low bioavail-
ability of non-injection administration. These problems greatly limit the use of 
protein drugs. Although researchers have improved the stability and absorption 
efficiency of protein drugs through methods such as PEG modification, microsphere 
sustained release, and liposome embedding, they still look forward to the emergence 
of better drug carriers. The application of EVs has brought dawn to this field.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a 
promising anticancer agent. Delivery of TRAIL through EVs can efficiently induce 
cancer cell apoptosis. When combined with dinaciclib, they inhibit the growth of 
drug-resistant tumors [43]. Immunosuppressive drugs must be taken after organ 
transplantation, but long-term use of these drugs increases the risk of infection 
and other serious diseases. Using bioengineering methods, researchers prepared 
exosome-like nanovesicles (NV) displaying the dual target cargo of PD-L1/CTLA-
4. These NVs enhanced the PD-L1/PD-1 and CTLA-4/CD80 immunosuppressive 
pathways and could be used as prospective immunosuppressive agents in organ 
transplantation [44]. Using extracellular nanovesicles to package CRISPR-Cas9 
protein and sgRNA to induce therapeutic exon skipping can avoid off-target 
mutagenesis and immunogenicity. And this method can achieve effective genome 
editing in a variety of cell types that are difficult to transfect, including human 
induced pluripotent stem cells (iPS), neurons and myoblasts [45]. Catalase could 
be loaded into exosomes by incubating at room temperature, saponins penetrating 
the membrane, repeated freezing and thawing and mechanical extrusion for the 
treatment of Parkinson’s disease (PD) [46].
Surface modification of EVs carrying protein drugs can greatly improve their 
targeting. In the study of stroke, nerve growth factor (NGF) exerts various neuro-
protective functions after ischemia. NGF was loaded into EVs with RVG peptide 
modification on the surface. Through systemic administration, NGF was effectively 
delivered to the ischemic cortex. The delivered NGF reduced inflammation by 
remodeling microglia polarization, promoted cell survival, and increased the 
number of neuroblast marker doublecortin-positive cells. The results of the study 
indicated the potential therapeutic effect of NGF@Exo (RVG) on stroke [47]. In 
addition, integrin αVβ5 exhibits tropism for the liver while integrin α6Vβ4 and inte-
grin α6β1 target lung [48, 49]. The iRGD specifically recognizes αV integrins on the 
surface of tumor cells [50]. RVG and c(RGDyK) peptides target brain tissue [51]. 
Klotho protein has the property of binding to circulating endothelial progenitor 
cells (EPCs) [52]. And chimeric antigen receptor (CAR) targeting specific tumor 
antigens and so on. These guiding molecules are utilized either by fusion with EVs 
membrane surface proteins (such as Lamp2b, VSVG, CD63, and other transmem-
brane proteins, etc.), or by chemical cross-linking on the surface of EVs to achieve 
the EVs targeting modification. Liu et al. summarized the surface modification 
strategies to improve the targeting of EVs (Figure 3) [53]. In addition, EVs derived 
from antigen-presenting cells with tumor antigens can be used as tumor vaccines to 
activate anti-tumor immune responses.
4.2 Methods of loading protein drugs into EVs
How to load protein drugs into EVs? There are currently the following strategies:
4.2.1 Expression of therapeutic protein in donor cells
Transfect donor cells with plasmids carrying the gene of interest. The cell will 
synthesize the target protein. These proteins are then secreted into EVs through a 
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natural packaging process. Subsequent separation and purification of EVs in the cell 
culture supernatant is sufficient [54]. Although this method seems simple and easy 
to implement, cytotoxicity, mixed interactions and impaired biological responses 
will provide great obstacles to the production of EVs. And the loading efficiency of 
the target protein is relatively low. Therefore, researchers have carried out various 
attempts to specifically load target proteins into EVs. For example, the fusion of 
therapeutic proteins with the constituent proteins of EVs and the specific modifica-
tion of therapeutic proteins.
4.2.2 Fusion of therapeutic protein with the constituent proteins of EVs
The therapeutic proteins are fused with the constituent proteins of EVs. Then 
they will be distributed into EVs mediated by the constituent proteins. This method 
can improve the specificity of protein loading into EVs. The fused constituent pro-
teins of EVs that have been tried include: CD63, Nef [55], vesicular stomatitis virus 
glycoprotein (VSVG) [56], apolipoprotein E (ApoE) [57], lysosome-associated 
membrane glycoprotein 2 (LAMP2B) [58], etc.
In addition, based on the idea of fusion proteins, researchers have developed 
a conditional loading method called "exosomes for protein loading via optically 
reversible protein-protein interaction (EXPLORs)" [59]. The principle is to couple 
the exosomal membrane protein CD9 with CIBN, and CRY 2 with the therapeutic 
protein. After light excitation, CIBN and CRY2 interact, and the therapeutic protein 
can be loaded into EVs through "photoreversible protein-protein interaction" [59].
All in all, the fusion expression of therapeutic proteins with the constituent 
proteins of EVs can indeed increase the enrichment level of therapeutic proteins in 
EVs. However, whether the fusion protein affects the uptake and function of the 
therapeutic protein by the recipient cells needs to be verified. Therefore, exploring 
the fusion of peptides that can play a sorting role with therapeutic proteins and 
minimize the impact on protein functions will become one of the research hotspots 
in the field of engineered EVs.
Figure 3. 
Design strategies for therapeutic exosome targeting [53].
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4.2.3 Specific modification of therapeutic protein
Currently, known protein modifications that can target therapeutic proteins 
into EVs mainly include two types. One is ubiquitination modification. The fusion 
of ubiquitin to the C-terminus of therapeutic protein can make the concentration 
of the fused therapeutic protein in EVs increased by nearly 10 times [60]. The 
other is to fuse the N-terminus of the therapeutic protein with a palmitoylated or 
myristoylated peptide, which can further increase the therapeutic protein in EVs 
[61]. However, it is still unknown whether the modification of proteins, especially 
ubiquitination, will cause the degradation of the therapeutic protein by the protea-
some and affect its function in the recipient cell.
4.2.4  Combined with mechanical methods to produce small vesicles containing 
therapeutic proteins
Expression of therapeutic protein in donor cells, combined with mechanical 
methods that pass through different pores, can produce small vesicles containing 
the therapeutic proteins [46, 62]. In addition, there are methods such as incuba-
tion at room temperature, permeabilization with saponin, freeze-thaw cycles and 
sonication, [46]. There are two main problems with engineered EVs obtained by 
mechanical methods. One is that the technical requirements for the separation and 
purification of EVs are relatively high. The second is the maintenance of the integ-
rity and biological activity of EVs. The composition of EVs actively produced by 
cells is different from the composition of mechanically produced EVs. The differ-
ence may affect the efficacy of engineered EVs. In the future application research of 
EVs, these two problems need to be solved and proved urgently.
So, what are the possible development directions for the existing cytotoxicity 
and the interaction of biological functions? The expression of tumor suppressor 
protein molecules may cause cytotoxicity to donor cells, which is not conducive to 
the production of EVs. If an inducible expression system is established, the coding 
DNA containing the inducible promoter is introduced into the donor cell to make 
the donor cell produce EVs containing the coding DNA, which will avoid cytotoxic-
ity to the donor cell. Then prepare EVs containing small molecules that induce DNA 
expression. The two types of EVs can be used in combination to express tumor sup-
pressor molecules in target cells. It can play a therapeutic role without affecting the 
production efficiency of EVs. The dual targeting of the two EVs will greatly reduce 
the impact of engineered EVs on non-targeted tissues. Because single-component 
EVs are randomly engulfed by cells and will not affect the cells. This may become 
one of the follow-up development directions in this field.
5.  Application of engineered EVs as carriers of small compounds in 
disease treatment
Chemotherapeutics and traditional Chinese medicine ingredients with 
anticancer effects are often used in the clinical treatment of a variety of malignant 
tumors. However, their toxic, side effects and short half-life limit their efficacy. 
The packaging and transportation with EVs will improve the targeting of 
chemotherapeutic drugs, increase the uptake efficiency of tumor cells, promote 
drug stability, reduce the use concentration, and reduce toxic side effects on 
other organs and normal tissues [63].
The hydrophobic drug curcumin could be packaged into exosomes by direct 
mixing for tumor treatment [64]. Paclitaxel (PTX) was loaded into EVs secreted by 
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macrophages by different methods such as room temperature incubation, electro-
poration and sonication. Studies have found that ultrasound treatment increases 
the load of EVs on drug molecules and the sustained release [65]. Small compounds 
can also be naturally secreted into EVs by incubating with donor cells. Incubation 
with paclitaxel make mesenchymal stromal cells produce microvesicles containing 
paclitaxel [66]. Injecting methotrexate-containing plasma membrane microvesicles 
(MTX-TMP) from apoptotic human tumor cells into the bile duct lumen of extrahe-
patic CCA patients could mobilize and activate neutrophils, and relieve the bile duct 
obstruction in 25% of patients, almost no adverse reactions [67].
At present, small molecule drugs are often loaded into EVs by passive  loading 
methods, such as direct mixing, incubation, ultrasonic treatment, vortexing, 
saponin permeation, repeated freezing and thawing, and mechanical extrusion. 
The disadvantages of these methods have always existed, that is, the loss and quality 
reduction of EVs caused by multiple purifications. In addition, long-term in vitro 
processing and the physical and chemical properties of drug molecules will also 
affect the biological activity and stability of EVs. Therefore, before EVs can be 
widely used in treatment, the storage methods and stability factors of EVs are also 
worthy of research.
6. Application of engineered EVs as virus carriers in gene therapy
Why are EVs a “stealth cap” for drugs? Because we know viruses to use them 
exactly like this. In nature, viruses "hijack" EVs to secrete and infect other cells. 
This method helps to provide a "cover" for the virus to prevent the virus from being 
cleared by the immune system or neutralized by antibodies, such as the infection 
process of HAV, HBV and HCV.
In gene therapy, currently widely used adeno-associated virus (AAV), oncolytic 
adenovirus (OAV) and lentivirus (LV) mediated gene therapy can cause the body’s 
immune response. After the same kind of AAV is used once, the body will produce 
a strong immune response, making the second injection ineffective. If EVs encap-
sulate viral particles to mediate their delivery, perhaps the therapeutic effect will 
be better.
Studies have shown that AAV isolated from conditioned media could bind to 
exosomes (exo-AAV) [68]. Compared with conventional AAV, exo-AAV was more 
resistant to neutralizing antibodies. After systemic injection in mice, compared 
with conventional AAV, exo-AAV delivered genes to the brain more efficiently at 
low vector doses. Importantly, no cytotoxicity was found in exo-AAV transduced 
cells. This may make exo-AAV widely used as a neuroscience research tool [68]. 
Compared with non-targeted modified EV-AAV, the expression of brain-targeting 
peptides on the surfaces of EVs can significantly enhance transduction [69].
In gene therapy of ophthalmic diseases, transferring genes to the retina is chal-
lenging. Because it requires a carrier system to overcome physical and biochemical 
barriers to enter and spread throughout the retinal tissue. After the exo-AAV was 
injected into the vitreous cavity (IVT), it was found that the expression of exo-
AAV was better than the traditional AAV. Exo-AAV exhibited a deeper penetration 
in the retina, effectively reaching the inner core and outer plexus, and to a lesser 
extent the outer nuclear layer. Exo-AAV is a reliable mouse retina gene delivery 
tool. Its simplicity of production and isolation makes it widely used in basic eye 
research [70].
Due to the low efficiency of gene delivery to the inner ear sensory hair cells. AAV 
is not so advanced in the field of gene therapy for hearing impairment. Studies have 
shown that Exo-AAV1-GFP is more effective than traditional AAV1-GFP, whether 
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injected in mouse cochlear explants in vitro or directly injected into the cochlea in 
vivo. Exo-AAV was not toxic in the body. Exo-AAV1 gene therapy partially rescued 
the hearing in a mouse model of hereditary deafness. It was a powerful hair cell 
gene delivery system that could be used for gene therapy of deafness [71].
Oncolytic viruses show unique anti-cancer mechanisms in cancer treatment. 
Chemotherapeutic drugs combined with oncolytic viruses showed stronger cyto-
toxicity and oncolytic effects. Someone has studied the systemic delivery of onco-
lytic adenovirus and paclitaxel encapsulated by EVs. The results have shown that 
this combination therapy enhanced anticancer effects in lung cancer models both 
in vitro and in vivo. EVs play a key role in the effective transmission of oncolytic 
viruses and chemotherapeutic drugs [72].
7. Sources of EVs that can be used for drug delivery
EVs currently used for therapeutic research are mainly derived from the 
 following sources: mesenchymal stem cells (MSCs), dendritic cells (DCs), tumor 
cells, red blood cells, macrophages and plants. EVs from different sources have 
different biological characteristics. Materials should be selected according to the 
purpose of treatment. The characteristics, advantages and disadvantages of EVs 
from different sources will be described below.
7.1 Mesenchymal stem cells
The MSCs involved in the study of EVs include adipose-derived MSCs, bone 
marrow MSCs, progenitor cells from different tissues, and so on. MSCs can be 
extracted from the patient’s bone marrow, fat, or other tissues. EVs derived from 
MSCs are very attractive. Because they have anti-inflammatory, anti-apoptotic and 
anti-microbial capability, and promote angiogenesis and the repair and regenera-
tion of damaged tissues. As mentioned above, EVs derived from MSCs have been 
widely used in the treatment of central nervous system diseases, cardiovascular 
diseases, bone and cartilage damage repair and regeneration, wound repair, and 
other organ damage repair and regeneration [7–21].
7.2 Dendritic cells
One potential source of therapeutic EVs is immature dendritic cells (imDCs). 
EVs secreted by imDCs lack surface markers such as CD40, CD86, MHC-I and 
MHC-II. Therefore, they have low immunogenicity. They can be isolated from 
CD34+ cells from the patient’s peripheral blood. It is one of the preferred sources of 
therapeutic EVs.
7.3 Tumor cells
The use of EVs derived from tumor cells to deliver drugs and vaccines for immu-
notherapy is very promising. Tumor EVs can deliver antigens to dendritic cells, 
thereby inducing T cell-mediated immune responses to tumor cells [73]. As tumor-
derived EVs specifically express Tetraspanins, they can target different tissues. This 
makes it possible to use tumor-derived EVs for tumor-targeting and selective drug 
delivery [74]. However, tumor-derived EVs also have many potential risks. Due to the 
presence of Tetraspanins, Urokinase plasminogen activator, Cathepsin D, Vimentin 
and other molecules derived from the surface of tumor cells [75, 76], they may 
promote tumor proliferation and metastasis, and Immunosuppressive effect [77–79].
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7.4 Red blood cells
Blood EVs mainly secreted by reticulocytes (RTC) are a potential source of safe 
and sufficient EVs. Because they integrate various membrane proteins including 
Transferrin (Tf) receptors, but they do not have any immune and cancer  stimulating 
activity [30]. Red blood cell EVs (RBCEV) also have the following advantages: 
large load; low self-nucleic acid content (red blood cells without nucleus and 
mitochondria); they can be delivered to a variety of different organs and tissues; 
large quantities of raw materials and easily available (the raw materials for producing 
RBCEVs are mainly O-type Blood of blood donors). Using blood EVs as carriers can 
efficiently target tumors to co-deliver chemotherapeutics and nucleic acid drugs. 
Significant tumor growth inhibitory effects were observed in tumor-bearing mice. 
There were no obvious side effects [30].
7.5 Macrophages
Macrophages are an important immune cell in the antigen-presenting cell 
 family. EVs derived from immune cells can mimic immune cells to target tumor 
cells. Macrophage EVs can transfer miRNAs or proteins to tumor cells, mediate 
tumor cell resistance to chemotherapy, promote cell invasion and other regulatory 
effects. Therefore, in the study of tumor treatment of EVs, in addition to using the 
targeting properties of macrophages-derived EVs, the influence of their contents 
must also be considered. It has been reported that the contents of EVs derived from 
macrophages can be removed. Then the EVs were used to carry chemotherapeutic 
drugs to achieve targeted therapy of triple-negative breast cancer [80].
7.6 Plant-derived EVs
Based on reliable sources and safety, fruits and plants have been used as alterna-
tive sources for the isolation of EVs for clinical use [81]. Plant-derived EVs have 
similar structural characteristics to animal cell-derived EVs. EVs from different 
plant sources have the physiological functions of the plant from which they are 
derived. For example, lemon-derived EVs have certain anti-cancer effects. Some 
researchers have tried to isolate lemon-derived EVs (LDEVs) for the treatment of 
gastric cancer. LDEVs caused s-phase arrest of gastric cancer cell cycle and induced 
cell apoptosis. LDEVs could be retained in the organs of the gastrointestinal tract 
and had strong anti-tumor activity against gastric cancer [82]. The isolated plant 
EVs can also be used after being engineered. Some researchers isolated EVs from 
grapefruit, modified the EVs in a targeted manner, and then loaded the anti-tumor 
drugs doxorubicin and curcumin. These modified EVs could target inflammatory 
tumors and have anti-inflammatory effects in mouse models [83].
Plant-derived EVs have a wide range of sources, are safe and non-toxic, have 
low immunogenicity, low cost, and are edible. They have great clinical application 
potential as edible chemotherapeutic drug carriers.
8. Commercialization progress and potential problems of EVs
8.1 Progress in the commercialization of EVs
So far, no EVs drugs have entered the clinic. Codiak BioSciences, a leading company 
in the development of engineered EVs as a new type of biopharmaceutical, uses its 
proprietary engEx platform to engineer EVs with different characteristics, load them 
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with various types of therapeutic molecules and change their orientation, so that they 
can reach specific cellular targets. Recently, Evox Therapeutics Ltd. and Eli Lilly and 
Co. reached a cooperation agreement to apply its exosome technology to the system to 
deliver RNA interference and antisense oligonucleotide drugs to the central nervous 
system, treating five unspecified Neurological diseases. Carmine Therapeutics is 
also a gene therapy company based on EVs, established in 2019. Carmine’s REGENT 
technology platform focuses on using red blood cell extracellular vesicles (RBCEV) as 
drug delivery vehicles. Mantra Bio also joined the emerging group of exosome drug 
development companies. With the deepening of research, more and more companies 
will join the field of EVs treatment.
8.2 EVs treatment and COVID-19
The Severe Acute Respiratory Syndrome (which first appeared in December 
2019) related to the new coronavirus (COVID-19) has rapidly developed into a pan-
demic, and the morbidity and mortality rates are increasing worldwide. COVID-19 
respiratory tract infection is characterized by an imbalanced immune response, 
leading to an increased possibility of severe respiratory disease and multiple organ 
disease.
Because EVs derived from MSCs have anti-inflammatory, anti-apoptotic and 
anti-microbial capability, promote angiogenesis and the repair and regeneration 
of damaged tissues. In related lung disease models, including acute lung injury 
and sepsis, systemic administration of MSC-EVs preparations can modulate 
immune responses. In a mouse model of pneumonia induced by Escherichia coli, 
it was found that MSC-EVs administration could enhance the phagocytosis of 
bacteria. In the pig model, MSC-EVs could reduce influenza virus-induced acute 
lung injury by inhibiting influenza virus replication. In other disease models, 
the disease alleviation effect of MSC-EVs on the inflammatory immune response 
has also been observed. It is speculated that they may also have anti-COVID-19 
efficacy. In cell therapy research for COVID-19, some registered clinical trials have 
turned their targets to EVs in the conditioned medium of MSCs. MSC-EVs can be 
administered intravenously (ChiCTR2000030484) or by inhalation (NCT04276987, 
ChiCTR2000030261).
However, before using MSC-EVs for COVID-19 patients, many other issues 
should be considered, such as the huge heterogeneity of MSC-EVs composition and 
source. In fact, comparing MSC-EVs harvested from the conditioned medium of 
bone marrow MSCs derived from different donors, there are significant differences 
in cytokine content and different therapeutic effects. In addition to immune regula-
tion, MSC-EVs can also control other biological processes and may cause unpredict-
able side effects. For example, increasing the risk of thrombosis.
In short, in order to reduce the risk of potential life-threatening side effects, 
International Society for Extracellular Vesicles (ISEV) and International Society 
for Cell and Gene Therapy (ISCT) strongly require that the clinical data from 
reasonable clinical trial should be carefully weighed. The EV preparations with 
good characteristics and produced under strict GMP conditions and appropriate 
regulatory supervision could be used. Any application of EVs should be carefully 
evaluated [84].
8.3 Potential problems in the industrialization of EVs
The potential application of EVs in new diagnostic and therapeutic strategies has 
attracted increasing attention. However, due to the inherent complex biogenesis of 
EVs and their huge heterogeneity in size, composition and source, the research of 
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EVs still faces huge challenges. It is necessary to establish a standardized method 
to solve the heterogeneity of EVs and the analysis of pre-processing and analysis of 
sources of variability in the study of EVs. The quality standards, extraction speci-
fications and especially the stability of preparation conditions for therapeutic EVs 
also need to be clarified.
In addition, the diversity and uncertainty of EVs content are also issues that need 
to be considered in the application. Before metastasis, malignant tumor cells use 
EVs to modify the microenvironment of the organ targeted by cancer metastasis, 
making it a suitable "soil" for tumor cell growth. The contents of EVs secreted by 
most tumor cells play a role in promoting tumor metastasis and progression. As 
mentioned earlier in this article, macrophage EVs can transfer miRNAs and proteins 
to tumor cells, mediate tumor cell resistance to chemotherapy, promote cell inva-
sion and other regulatory effects. Therefore, if EVs from such sources are used as 
drug carriers, it is particularly important to first remove the adverse effects of their 
contents.
9. Conclusion
As an important medium of intercellular communication, EVs play an important 
physiological function and are also involved in the occurrence and development of 
a variety of diseases. In recent years, there have been numerous studies on the treat-
ment of related diseases with EVs from different cell sources, and EV has shown 
its unique advantages in drug transportation. EVs are similar to natural liposomes, 
which can enhance the function of EVs to treat specific diseases through target-
ing modification and delivery of functional active substances and other technical 
modifications according to the characteristics of different diseases. EVs with 
improved function have shown obvious advantages in the treatment of tumors and 
difficult diseases of central nervous system. However, the clinical application of EVs 
technology is still in its infancy, and the challenges it faces are accompanied by the 
possibility of numerous new discoveries and new technologies. We expect that with 
the continuous in-depth research, EVs as a new drug carrier in the treatment of a 
variety of diseases will bring more and greater surprises.
Acknowledgements
This work was supported by the National Key R&D Program of China 
(2018YFA0900900), and the National Natural Science Foundation of China 
(81773251 and 81702735).
Theranostics - An Old Concept in New Clothing
16
Author details
Chunying Liu, Xuejing Lin and Changqing Su*
Department of Molecular Oncology, National Center for Liver Cancer, 
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 
Shanghai, China
*Address all correspondence to: suchangqing@gmail.com
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
17
Extracellular Vesicles: “Stealth Transport Aircrafts” for Drugs
DOI: http://dx.doi.org/10.5772/intechopen.94502
References
[1] Gurunathan S, Kang MH, Jeyaraj M, 
Qasim M, Kim JH. Review of the 
isolation, characterization, biological 
function, and multifarious therapeutic 
approaches of exosomes. Cells. 
2019;8:307. DOI: 10.3390/cells8040307
[2] Shao H, Im H, Castro CM, 
Breakefield X, Weissleder R, Lee H. 
New technologies for analysis of 
extracellular vesicles. Chem Rev. 
2018;118:1917-50. DOI: 10.1021/acs.
chemrev.7b00534
[3] Théry C, Zitvogel L, Amigorena S. 
Exosomes: composition, biogenesis and 
function. Nat Rev Immunol. 2002;2:569-
79. DOI: 10.1038/nri855
[4] Colombo M, Raposo G, Théry C. 
Biogenesis, secretion, and intercellular 
interactions of exosomes and other 
extracellular vesicles. Annu Rev Cell 
Dev Biol. 2014;30:255-89. DOI: 10.1146/
annurev-cellbio-101512-122326
[5] van Niel G, D’Angelo G, Raposo G. 
Shedding light on the cell biology of 
extracellular vesicles. Nat Rev Mol Cell 
Biol. 2018;19:213-28. DOI: 10.1038/
nrm.2017.125
[6] Kamerkar S, LeBleu VS, Sugimoto H, 
Yang S, Ruivo CF, Melo SA, et al. 
Exosomes facilitate therapeutic 
targeting of oncogenic KRAS in 
pancreatic cancer. Nature. 2017;546: 
498-503. DOI: 10.1038/nature22341
[7] Li L, Zhang Y, Mu J, Chen J, 
Zhang C, Cao H, et al. Transplantation 
of human mesenchymal stem cell-
derived exosomes immobilized in 
an adhesive hydrogel for effective 
treatment of spinal cord injury. Nano 
Lett. 2020;20:4298-305. DOI: 10.1021/
acs.nanolett.0c00929
[8] Hu G, Xia Y, Zhang J, Chen Y, 
Yuan J, Niu X, et al. ESC-sEVs 
rejuvenate senescent hippocampal 
NSCs by activating lysosomes to 
improve cognitive dysfunction in 
vascular dementia. Adv Sci (Weinh). 
2020;7:1903330. DOI: 10.1002/
advs.201903330
[9] Wu Q , Wang J, Tan WLW, Jiang Y, 
Wang S, Li Q , et al. Extracellular 
vesicles from human embryonic stem 
cell-derived cardiovascular progenitor 
cells promote cardiac infarct healing 
through reducing cardiomyocyte death 
and promoting angiogenesis. Cell 
Death Dis. 2020;11:354. DOI: 10.1038/
s41419-020-2508-y
[10] Khan M, Nickoloff E, Abramova T, 
Johnson J, Verma SK, Krishnamurthy P, 
et al. Embryonic stem cell-derived 
exosomes promote endogenous repair 
mechanisms and enhance cardiac 
function following myocardial 
infarction. Circulation research. 
2015;117:52-64. DOI: 10.1161/
CIRCRESAHA.117.305990
[11] Wang Y, Zhang L, Li Y, Chen L, 
Wang X, Guo W, et al. Exosomes/
microvesicles from induced pluripotent 
stem cells deliver cardioprotective 
miRNAs and prevent cardiomyocyte 
apoptosis in the ischemic myocardium. 
International journal of cardiology. 
2015;192:61-9. DOI: 10.1016/j.
ijcard.2015.05.020
[12] Bouchareychas L, Duong P, 
Covarrubias S, Alsop E, Phu TA, 
Chung A, et al. Macrophage exosomes 
resolve atherosclerosis by regulating 
hematopoiesis and inflammation 
via microRNA cargo. Cell Rep. 
2020;32:107881. DOI: 10.1016/j.
celrep.2020.107881
[13] Lei X, He N, Zhu L, Zhou M, 
Zhang K, Wang C, et al. Mesenchymal 
stem cell-derived extracellular vesicles 
attenuate radiation-induced lung injury 
via miRNA-214-3p. Antioxid Redox 
Signal. 2020. DOI: 10.1089/ars.2019.7965
Theranostics - An Old Concept in New Clothing
18
[14] Hu S, Li Z, Lutz H, Huang K, 
Su T, Cores J, et al. Dermal exosomes 
containing miR-218-5p promote hair 
regeneration by regulating β-catenin 
signaling. Sci Adv. 2020;6:eaba1685. 
DOI: 10.1126/sciadv.aba1685
[15] Yan B, Zhang Y, Liang C, Liu B, 
Ding F, Wang Y, et al. Stem cell-derived 
exosomes prevent pyroptosis and repair 
ischemic muscle injury through a novel 
exosome/circHIPK3/ FOXO3a pathway. 
Theranostics. 2020;10:6728-42. DOI: 
10.7150/thno.42259
[16] Zhang S, Yang Y, Jia S, Chen H, 
Duan Y, Li X, et al. Exosome-like 
vesicles derived from Hertwig’s 
epithelial root sheath cells promote 
the regeneration of dentin-pulp tissue. 
Theranostics. 2020;10:5914-31. DOI: 
10.7150/thno.43156
[17] Bian B, Zhao C, He X, Gong Y, 
Ren C, Ge L, et al. Exosomes derived 
from neural progenitor cells preserve 
photoreceptors during retinal 
degeneration by inactivating microglia. 
J Extracell Vesicles. 2020;9:1748931. 
DOI: 10.1080/20013078.2020.1748931
[18] Fafián-Labora JA, Rodríguez-
Navarro JA, O’Loghlen A. Small 
extracellular vesicles have GST activity 
and ameliorate senescence-related tissue 
damage. Cell Metab. 2020;32:71-86 e5. 
DOI: 10.1016/j.cmet.2020.06.004
[19] Li CJ, Fang QH, Liu ML, Lin JN. 
Current understanding of the role of 
Adipose-derived Extracellular Vesicles 
in Metabolic Homeostasis and Diseases: 
Communication from the distance 
between cells/tissues. Theranostics. 
2020;10:7422-35. DOI: 10.7150/thno.42167
[20] Zhang H, Wang J, Ren T, 
Huang Y, Liang X, Yu Y, et al. Bone 
marrow mesenchymal stem cell-
derived exosomal miR-206 inhibits 
osteosarcoma progression by targeting 
TRA2B. Cancer Lett. 2020;490:54-65. 
DOI: 10.1016/j.canlet.2020.07.008
[21] He Z, Li W, Zheng T, Liu D, Zhao S. 
Human umbilical cord mesenchymal 
stem cells-derived exosomes deliver 
microRNA-375 to downregulate ENAH 
and thus retard esophageal squamous 
cell carcinoma progression. J Exp Clin 
Cancer Res. 2020;39:140. DOI: 10.1186/
s13046-020-01631-w
[22] Gazdic M, Volarevic V, Harrell CR, 
Fellabaum C, Jovicic N, Arsenijevic N, 
et al. Stem cells therapy for spinal 
cord injury. Int J Mol Sci. 2018 Mar 
30;19:1039. DOI: 10.3390/ijms19041039
[23] González C, Bonilla S, Flores AI, 
Cano E, Liste I. An update on human 
stem cell-based therapy in Parkinson’s 
disease. Curr Stem Cell Res Ther. 
2016;11:561-8. DOI: 10.2174/1574888x10
666150531172612
[24] Tang W. Challenges and 
advances in stem cell therapy. Biosci 
Trends. 2019;13:286. DOI: 10.5582/
bst.2019.01241
[25] Isomi M, Sadahiro T, Ieda M. 
Progress and challenge of cardiac 
regeneration to treat heart failure. J 
Cardiol. 2019;73:97-101. DOI: 10.1016/j.
jjcc.2018.10.002
[26] Adamiak M, Cheng G, Bobis-
Wozowicz S, Zhao L, Kedracka-Krok S, 
Samanta A, et al. Induced pluripotent 
stem cell (iPSC)-derived extracellular 
vesicles are safer and more effective 
for cardiac repair than iPSCs. Circ 
Res. 2018;122:296-309. DOI: 10.1161/
CIRCRESAHA.117.311769
[27] Dougherty JA, Kumar N, Noor M, 
Angelos MG, Khan M, Chen CA. 
Extracellular vesicles released by human 
induced-pluripotent stem cell-derived 
cardiomyocytes promote angiogenesis. 
Front Physiol. 2018;9:1794. DOI: 
10.3389/fphys.2018.01794
[28] Kato T, Fahrmann JF, Hanash SM, 
Vykoukal J. Extracellular vesicles 
mediate B cell immune response and 
19
Extracellular Vesicles: “Stealth Transport Aircrafts” for Drugs
DOI: http://dx.doi.org/10.5772/intechopen.94502
are a potential target for cancer therapy. 
Cells. 2020;9:1518. DOI: 10.3390/
cells9061518
[29] Usman WM, Pham TC, Kwok YY, 
Vu LT, Ma V, Peng B, et al. Efficient 
RNA drug delivery using red blood 
cell extracellular vesicles. Nat 
Commun. 2018;9:2359. DOI: 10.1038/
s41467-018-04791-8
[30] Zhan Q , Yi K, Qi H, Li S, Li X, 
Wang Q , et al. Engineering blood 
exosomes for tumor-targeting efficient 
gene/chemo combination therapy. 
Theranostics. 2020;10:7889-905. DOI: 
10.7150/thno.45028
[31] Xu Q , Zhang Z, Zhao L, Qin Y, 
Cai H, Geng Z, et al. Tropism-facilitated 
delivery of CRISPR/Cas9 system with 
chimeric antigen receptor-extracellular 
vesicles against B-cell malignancies. J 
Control Release. 2020;326:455-67. DOI: 
10.1016/j.jconrel.2020.07.033
[32] Yang L, Han B, Zhang Z, Wang S, 
Bai Y, Zhang Y, et al. Extracellular 
vesicle-mediated delivery of circular 
RNA SCMH1 promotes functional 
recovery in rodent and nonhuman 
primate ischemic stroke models. 
Circulation. 2020;142:556-74. DOI: 
10.1161/CIRCULATIONAHA.120.045765
[33] Wang X, Zhang H, Bai M, Ning T, 
Ge S, Deng T, et al. Exosomes serve as 
nanoparticles to deliver anti-miR-214 to 
reverse chemoresistance to cisplatin in 
gastric cancer. Mol Ther. 2018;26:774-83. 
DOI: 10.1016/j.ymthe.2018.01.001
[34] Yang T, Fogarty B, LaForge B, 
Aziz S, Pham T, Lai L, et al. Delivery 
of small interfering RNA to inhibit 
vascular endothelial growth factor in 
zebrafish using natural brain endothelia 
cell-secreted exosome nanovesicles 
for the treatment of brain cancer. 
AAPS J. 2016;19:475-86. DOI: 10.1208/
s12248-016-0015-y
[35] Alvarez-Erviti L, Seow Y, Yin H, 
Betts C, Lakhal S, Wood MJ. Delivery of 
siRNA to the mouse brain by systemic 
injection of targeted exosomes. Nat 
Biotechnol. 2011;29:341-5. DOI: 10.1038/
nbt.1807
[36] Luo Q , Guo D, Liu G, Chen G, 
Hang M, Jin M. Exosomes from 
miR-126-overexpressing Adscs 
are therapeutic in relieving acute 
myocardial ischaemic injury. Cell 
Physiol Biochem. 2017;44:2105-16. DOI: 
10.1159/000485949
[37] Zhang H, Wang Y, Bai M, Wang J, 
Zhu K, Liu R, et al. Exosomes serve as 
nanoparticles to suppress tumor growth 
and angiogenesis in gastric cancer by 
delivering hepatocyte growth factor 
siRNA. Cancer Sci. 2017;109:629-41. 
DOI: 10.1111/cas.13488
[38] Kojima R, Bojar D, Rizzi G, 
Hamri GC, El-Baba MD, Saxena P, 
et al. Designer exosomes produced by 
implanted cells intracerebrally deliver 
therapeutic cargo for Parkinson’s disease 
treatment. Nat Commun. 2018;9:1305. 
DOI: 10.1038/s41467-018-03733-8
[39] Batagov AO, Kuznetsov VA, 
Kurochkin IV. Identification of 
nucleotide patterns enriched in 
secreted RNAs as putative cis-acting 
elements targeting them to exosome 
nano-vesicles. BMC Genomics. 
2011;12 Suppl 3(Suppl 3):S18. DOI: 
10.1186/1471-2164-12-S3-S18
[40] Ausländer S, Ausländer D, 
Müller M, Wieland M, Fussenegger M. 
Programmable single-cell mammalian 
biocomputers. Nature. 2012;487:123-7. 
DOI: 10.1038/nature11149
[41] Saito H, Fujita Y, Kashida S, 
Hayashi K, Inoue T. Synthetic human 
cell fate regulation by protein-
driven RNA switches. Nat Commun. 
2011;2:160. DOI: 10.1038/ncomms1157
[42] Saito H, Kobayashi T, Hara T, 
Fujita Y, Hayashi K, Furushima R, et al. 
Synthetic translational regulation by 
Theranostics - An Old Concept in New Clothing
20
an L7Ae-kink-turn RNP switch. Nat 
Chem Biol. 2010;6:71-8. DOI: 10.1038/
nchembio.273
[43] Ke C, Hou H, Li J, Su K, Huang C, 
Lin Y, et al. Extracellular vesicle 
delivery of TRAIL eradicates resistant 
tumor growth in combination with 
CDK inhibition by Dinaciclib. Cancers 
(Basel). 2020;12:1157. DOI: 10.3390/
cancers12051157
[44] Xu Z, Tsai HI, Xiao Y, Wu Y, Su D, 
Yang M, et al. Engineering programmed 
death ligand-1/cytotoxic T-lymphocyte-
associated antigen-4 dual-targeting 
nanovesicles for immunosuppressive 
therapy in transplantation. ACS 
Nano. 2020;14:7959-69. DOI: 10.1021/
acsnano.9b09065
[45] Gee P, Lung MSY, Okuzaki Y, 
Sasakawa N, Iguchi T, Makita Y, et al. 
Extracellular nanovesicles for packaging 
of CRISPR-Cas9 protein and sgRNA to 
induce therapeutic exon skipping. Nat 
Commun. 2020;11:1334. DOI: 10.1038/
s41467-020-14957-y
[46] Haney MJ, Klyachko NL, Zhao Y, 
Gupta R, Plotnikova EG, He Z, et al. 
Exosomes as drug delivery vehicles for 
Parkinson’s disease therapy. J Control 
Release. 2015;207:18-30. DOI: 10.1016/j.
jconrel.2015.03.033
[47] Yang J, Wu S, Hou L, Zhu D, Yin S, 
Yang G, et al. Therapeutic effects of 
simultaneous delivery of nerve growth 
factor mRNA and protein via exosomes 
on cerebral ischemia. Mol Ther Nucleic 
Acids. 2020;21:512-22. DOI: 10.1016/j.
omtn.2020.06.013
[48] Hoshino A, Costa-Silva B, 
Shen TL, Rodrigues G, Hashimoto A, 
Tesic Mark M, et al. Tumour exosome 
integrins determine organotropic 
metastasis. Nature. 2015;527:329-35. 
DOI: 10.1038/nature15756
[49] Rak J. Cancer: Organ-seeking 
vesicles. Nature. 2015;527:312-4. DOI: 
10.1038/nature15642
[50] Tian Y, Li S, Song J, Ji T, Zhu M, 
Anderson GJ, et al. A doxorubicin 
delivery platform using engineered 
natural membrane vesicle exosomes for 
targeted tumor therapy. Biomaterials. 
2014;35:2383-90. DOI: 10.1016/j.
biomaterials.2013.11.083
[51] Yang J, Zhang X, Chen X, Wang L, 
Yang G. Exosome mediated delivery 
of miR-124 promotes neurogenesis 
after ischemia. Mol Ther Nucleic 
Acids. 2017;7:278-87. DOI: 10.1016/j.
omtn.2017.04.010
[52] Chen W, Yang M, Bai J, Li X, Kong X, 
Gao Y, et al. Exosome-modified tissue 
engineered blood vessel for endothelial 
progenitor cell capture and targeted 
siRNA delivery. Macromol Biosci. 
2018;18. DOI: 10.1002/mabi.201700242
[53] Liu C, Su C. Design strategies and 
application progress of therapeutic 
exosomes. Theranostics. 2019;9:1015-28. 
DOI: 10.7150/thno.30853
[54] Hall J, Prabhakar S, Balaj L, 
Lai CP, Cerione RA, Breakefield XO. 
Delivery of therapeutic proteins via 
extracellular vesicles: Review and 
potential treatments for Parkinson’s 
disease, glioma, and schwannoma. Cell 
Mol Neurobiol. 2016;36:417-27. DOI: 
10.1007/s10571-015-0309-0
[55] Di Bonito P, Chiozzini C, 
Arenaccio C, Anticoli S, Manfredi F, 
Olivetta E, et al. Antitumor HPV 
E7-specific CTL activity elicited by in 
vivo engineered exosomes produced 
through DNA inoculation. Int J 
Nanomedicine. 2017;12:4579-91. DOI: 
10.2147/IJN.S131309
[56] Meyer C, Losacco J, Stickney Z, 
Li L, Marriott G, Lu B. Pseudotyping 
exosomes for enhanced protein delivery 
in mammalian cells. Int J Nanomedicine. 
2017;12:3153-70. DOI: 10.2147/IJN.
S133430
[57] Zheng P, Luo Q , Wang W, Li J, 
Wang T, Wang P, et al. Tumor-associated 
21
Extracellular Vesicles: “Stealth Transport Aircrafts” for Drugs
DOI: http://dx.doi.org/10.5772/intechopen.94502
macrophages-derived exosomes promote 
the migration of gastric cancer cells by 
transfer of functional Apolipoprotein E. 
Cell Death Dis. 2018;9:434. DOI: 
10.1038/s41419-018-0465-5
[58] Simpson RJ, Jensen SS, Lim JW. 
Proteomic profiling of exosomes: 
current perspectives. Proteomics. 
2008;8:4083-99. DOI: 10.1002/
pmic.200800109
[59] Yim N, Ryu SW, Choi K, Lee KR, 
Lee S, Choi H, et al. Exosome 
engineering for efficient intracellular 
delivery of soluble proteins using 
optically reversible protein-protein 
interaction module. Nat Commun. 
2016;7:12277. DOI: 10.1038/ncomms12277
[60] Cheng Y, Schorey JS. Targeting 
soluble proteins to exosomes using 
a ubiquitin tag. Biotechnol Bioeng. 
2015;113:1315-24. DOI: 10.1002/
bit.25884
[61] Shen B, Wu N, Yang JM, Gould SJ. 
Protein targeting to exosomes/
microvesicles by plasma membrane 
anchors. J Biol Chem. 2011;286:14383-
95. DOI: 10.1074/jbc.M110.208660
[62] Wan Y, Wang L, Zhu C, Zheng 
Q , Wang G, Tong J, et al. Aptamer-
conjugated extracellular nanovesicles 
for targeted drug delivery. Cancer Res. 
2018;78:798-808. DOI: 10.1158/0008-
5472.CAN-17-2880
[63] Zhang D, Qin X, Wu T, Qiao Q , 
Song Q , Zhang Z. Extracellular vesicles 
based self-grown gold nanopopcorn for 
combinatorial chemo-photothermal 
therapy. Biomaterials. 2019;197:220-8. 
DOI: 10.1016/j.biomaterials.2019.01.024
[64] Zarovni N, Corrado A, Guazzi P, 
Zocco D, Lari E, Radano G, et al. 
Integrated isolation and quantitative 
analysis of exosome shuttled proteins 
and nucleic acids using immunocapture 
approaches. Methods. 2015;87:46-58. 
DOI: 10.1016/j.ymeth.2015.05.028
[65] Kim MS, Haney MJ, Zhao Y, 
Mahajan V, Deygen I, Klyachko NL, 
et al. Development of exosome-
encapsulated paclitaxel to overcome 
MDR in cancer cells. Nanomedicine. 
2015;12:655-64. DOI: 10.1016/j.
nano.2015.10.012
[66] Pascucci L, Coccè V, Bonomi A, 
Ami D, Ceccarelli P, Ciusani E, 
et al. Paclitaxel is incorporated by 
mesenchymal stromal cells and 
released in exosomes that inhibit in 
vitro tumor growth: a new approach 
for drug delivery. J Control Release. 
2014;192:262-70. DOI: 10.1016/j.
jconrel.2014.07.042
[67] Gao Y, Zhang H, Zhou N, Xu P, 
Wang J, Jin X, et al. Methotrexate-loaded 
tumour-cell-derived microvesicles can 
relieve biliary obstruction in patients 
with extrahepatic cholangiocarcinoma. 
Nat Biomed Eng. 2020;4:743-53. DOI: 
10.1038/s41551-020-0583-0
[68] Hudry E, Martin C, Gandhi S, 
György B, Scheffer DI, Mu D, et al. 
Exosome-associated AAV vector as a 
robust and convenient neuroscience 
tool. Gene Ther. 2016;23:380-92. DOI: 
10.1038/gt.2016.11
[69] György B, Fitzpatrick Z, 
Crommentuijn MH, Mu D, Maguire CA. 
Naturally enveloped AAV vectors 
for shielding neutralizing antibodies 
and robust gene delivery in vivo. 
Biomaterials. 2014;35:7598-609. DOI: 
10.1016/j.biomaterials.2014.05.032
[70] Wassmer SJ, Carvalho LS, 
György B, Vandenberghe LH, 
Maguire CA. Exosome-associated AAV2 
vector mediates robust gene delivery 
into the murine retina upon intravitreal 
injection. Sci Rep. 2017;7:45329. DOI: 
10.1038/srep45329
[71] György B, Sage C, Indzhykulian AA, 
Scheffer DI, Brisson AR, Tan S, 
et al. Rescue of hearing by gene 
delivery to inner-ear hair cells using 
Theranostics - An Old Concept in New Clothing
22
exosome-associated AAV. Mol Ther. 
2017;25:379-91. DOI: 10.1016/j.
ymthe.2016.12.010
[72] Garofalo M, Saari H, Somersalo P, 
Crescenti D, Kuryk L, Aksela L, et al. 
Antitumor effect of oncolytic virus and 
paclitaxel encapsulated in extracellular 
vesicles for lung cancer treatment. J 
Control Release. 2018;283:223-34. DOI: 
10.1016/j.jconrel.2018.05.015
[73] Wolfers J, Lozier A, Raposo G, 
Regnault A, Théry C, Masurier C, et al. 
Tumor-derived exosomes are a source of 
shared tumor rejection antigens for CTL 
cross-priming. Nat Med. 2001;7:297-303. 
DOI: 10.1038/85438
[74] Rana S, Yue S, Stadel D, Zöller M. 
Toward tailored exosomes: the exosomal 
tetraspanin web contributes to target 
cell selection. Int J Biochem Cell Biol. 
2012;44:1574-84. DOI: 10.1016/j.
biocel.2012.06.018
[75] Zomer A, Maynard C, Verweij FJ, 
Kamermans A, Schäfer R, Beerling E, 
et al. In vivo imaging reveals 
extracellular vesicle-mediated 
phenocopying of metastatic behavior. 
Cell. 2015;161:1046-57. DOI: 10.1016/j.
cell.2015.04.042
[76] Harris DA, Patel SH, Gucek M, 
Hendrix A, Westbroek W, Taraska JW. 
Exosomes released from breast cancer 
carcinomas stimulate cell movement. 
PLoS One. 2015;10:e0117495. DOI: 
10.1371/journal.pone.0117495
[77] Tomihari M, Chung JS, Akiyoshi H, 
Cruz PD, Jr., Ariizumi K. DC-HIL/
glycoprotein Nmb promotes growth 
of melanoma in mice by inhibiting the 
activation of tumor-reactive T cells. 
Cancer Res. 2010;70:5778-87. DOI: 
10.1158/0008-5472.CAN-09-2538
[78] Kim JW, Wieckowski E, Taylor DD, 
Reichert TE, Watkins S, Whiteside TL. 
Fas ligand-positive membranous vesicles 
isolated from sera of patients with oral 
cancer induce apoptosis of activated 
T lymphocytes. Clin Cancer Res. 
2005;11:1010-20.
[79] Luan X, Sansanaphongpricha K, 
Myers I, Chen H, Yuan H, Sun D. 
Engineering exosomes as refined 
biological nanoplatforms for drug 
delivery. Acta Pharmacol Sin. 
2017;38:754-63. DOI: 10.1038/
aps.2017.12
[80] Li S, Wu Y, Ding F, Yang J, Li J, 
Gao X, et al. Engineering macrophage-
derived exosomes for targeted 
chemotherapy of triple-negative breast 
cancer. Nanoscale. 2020;12:10854-62. 
DOI: 10.1039/d0nr00523a
[81] Ju S, Mu J, Dokland T, Zhuang X, 
Wang Q , Jiang H, et al. Grape exosome-
like nanoparticles induce intestinal 
stem cells and protect mice from DSS-
induced colitis. Mol Ther. 2013;21:1345-
57. DOI: 10.1038/mt.2013.64
[82] Yang M, Liu X, Luo Q , Xu L, 
Chen F. An efficient method to 
isolate lemon derived extracellular 
vesicles for gastric cancer therapy. J 
Nanobiotechnology. 2020;18:100. DOI: 
10.1186/s12951-020-00656-9
[83] Wang Q , Ren Y, Mu J, Egilmez NK, 
Zhuang X, Deng Z, et al. Grapefruit-
derived nanovectors use an activated 
leukocyte trafficking pathway to deliver 
therapeutic agents to inflammatory 
tumor sites. Cancer Res. 2015;75:2520-9. 
DOI: 10.1158/0008-5472.CAN-14-3095
[84] Börger V, Weiss DJ, Anderson JD, 
Borràs FE, Bussolati B, Carter DRF, 
et al. International Society for 
Extracellular Vesicles and International 
Society for Cell and Gene Therapy 
statement on extracellular vesicles 
from mesenchymal stromal cells 
and other cells: considerations for 
potential therapeutic agents to suppress 
coronavirus disease-19. Cytotherapy. 
2020;22:482-5. DOI: 10.1016/j.
jcyt.2020.05.002
